Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
The Cancer Journal From Scientific American|March 1, 1997
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541M Roach, C Cirrincione, D Budman, et al.Gene|October 31, 2000
Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cellsJ Shan, J M Mason, L Yuan, et al.American Journal of Clinical Oncology|August 1, 1991
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trialS M Lichtman, D Budman, H Bosworth, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1986
A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patientsV Vinciguerra, T J Degnan, A Sciortino, et al.Cancer Treatment Reports|September 1, 1981
Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomasG J Vosika, K Briscoe, R W Carey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1995
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancerS Jones, E Winer, C Vogel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281J Aisner, C Cirrincione, M Perloff, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.Age and Ageing|May 1, 1992
Use of cisplatin for elderly patientsS M Lichtman, M Buchholtz, J Marino, et al.Cancer Research|April 1, 1985
Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancerG F Stanton, V Raymond, R E Wittes, et al.Pageof 3